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to directly target the nerves. Alcohol is administered using a single
infusion in the main renal artery. Doses of 0.15 to 0.6 mL have been
studied in this model. The denervation produced with alcohol has
been characterized with histology, immunostaining and measurement
of renal norepinephrine (NE) in a porcine model. A direct comparison
of the denervation produced with alcohol vs. RF was performed using
the same model and methods (3 mos. survival). For the RF group 4
renal artery ablations were performed, with one ablation per
quadrant.
RESULTS Renal denervation with alcohol creates consistent, dose-
related and substantial sympathetic nerve injury. The Peregrine
catheter delivers the alcohol directly within the adventitia and peri-
adventitial space. Because the alcohol is infused outside of the vessel
wall, changes to the media are rare; typically mild and focal; and at
the abluminal surface of the media. This contrasts with RF, which
typically creates focal transmural medial injury. The ablation area
produced by the infusion of alcohol is larger, and typically circum-
ferential, in comparison to the focal ablation produced by RF. Ablation
depth (distance from the lumen) and area (morphometric) were
signiﬁcantly greater for alcohol using 0.3 mL and 0.6 mL per artery,
compared to RF. Depth (p<0.05 for both alcohol doses) compared to
RF: 0.3 mL ¼ 6.61.2 mm, 0.6 mL ¼ 8.22.2 mm, RF ¼ 3.91.2 mm.
Area (p¼0.0001): 0.3 mL ¼ 30.813.7 mm2, 0.6 mL ¼ 41.67.5 mm2,
RF ¼ 11.07.5 mm2. Compared to controls the median NE was reduced
by 83% for 0.6 mL, 76% for 0.3 mL and 66% for RF (p¼0.095 both
alcohol vs. RF). The median procedure time for the alcohol groups was
9 min. vs. 29 min. for RF (p<0.05). Neither RF nor alcohol infusion
produced any systemic or renal adverse events.
CONCLUSIONS The use of alcohol with the Peregrine System for
“chemical” renal denervation appears to be potentially safer and more
time efﬁcient than RF. Alcohol-mediated denervation appears to
address the issue of adequacy of denervation by demonstrating su-
perior coverage in terms of ablation depth and area, yielding a greater
reduction in renal NE vs. RF. Chemical denervation can also be per-
formed in very short renal arteries, avoiding technical issues and
adverse events associated with treating the entire length of the artery,
or the distal branches as has been proposed for RF. Overall, chemical
denervation using alcohol may represent a promising alternative to
RF ablation.
CATEGORIES ENDOVASCULAR: Hypertension Therapies and Renal
Denervation
KEYWORDS Hypertension, Peripheral, Renal denervation
TCT-89
Renal Sympathetic Denervation in Treatment Resistant Essential
Hypertension. A Sham-Controlled, Double-blinded Randomized
Trial (ReSET trial)
Ole N. Mathiassen,1 Jesper N. Bech,2 Niels Henrik Buus,3
Kent L. Christensen,1 Henrik Vase,1 Jannik B. Bertelsen,1 Rickers Hans,4
Ulla Kampmann,5 Morten E. Pedersen,1 Ole L. Pedersen,6
Christian D. Peters,3 Per L. Poulsen,5 Jens F. Lassen,1 Klavs Würgler,7
Hans Erik Boetker,1 Pauline Schroeder,6 Erling B. Pedersen,8
Anne Kaltoft1
1Dept. of Cardiology, Aarhus Universityhospital, Skejby, Denmark,
Aarhus, Denmark; 2Holstebro Hospital, Holstebro, Denmark; 3Dept. of
Nephrology, Aarhus University Hospital, Skejby, Aarhus, Denmark;
4Randers Hospital, Randers, Denmark; 5Dept. of Endocrinology, Aarhus
University Hospital, NBG, Aarhus, Denmark; 6Viborg Hospital, Viborg,
Denmark; 7Silkeborg Hospital, Silkeborg, Denmark; 8Holstebro
Hospital, Holstebro, Denamrk
BACKGROUND Renal denervation (RDN) for the treatment of
resistant hypertension has been shown in pilot studies to lower blood
pressure (BP) without safety alerts. However, this was only shown in
open la-belled study designs and has primarily addressed the effect
on ofﬁce BP. We therefore conducted a sham controlled, double
blind randomized single center trial to establish reliable efﬁcacy
data based on 24-h BP measurements. We expected a 10 mmHg
reduction in ABPM systolic daytime BP (ASBP-day) at 3 months in the
RDN group as compared to SHAM, and planned to randomize 70
patients.
METHODS Patients with therapy resistant essential hypertension, 30
to 70 years of age, were randomly as-signed to undergo RDN or a sham
procedure. Inclusion criteria were ASBP-day  145 mmHg follow one
month of stable medication and 2 weeks of compliance registration.Recruitment and patient follow-up was held in seven dedicated hy-
pertension out-patient clinics. Drug treatment was optional, apart
from the mandatory use of a diuretic when tolerated by the
patient. Follow-up changes in antihypertensive medication were
only allowed if requested by the patient or if harm-full changes in
BP or safety parameters occurred. Renal artery anatomy was evalu-
ated by CT angio in advance. All RDN procedures were carried out by
the same experienced operator using the simplicity catheter
(Medtronic).
RESULTS 69 patients, mean age 56  9 year, were randomized for
RDN (n ¼ 36) or SHAM (n ¼ 33). One patient suffered a NSTEMI close to
randomization and was excluded. Groups showed similar demog-
raphy and baseline parameters. Mean baseline ASBP was 159 
12 mmHg (RDN) and 159  14 mmHg (SHAM). Groups had similar re-
ductions in ASBP compared to baseline at 3 months: - 6.2 
18.8 mmHg (RDN) vs. - 6.0  13.5 mmHg (SHAM) and at 6 months: - 6.1
 18.9 mmHg (RDN) vs. - 4.3  15.1 mmHg (SHAM). Mean antihyper-
tensive DDD usage at 3 month was equal 6.8  2.7 (RDN) vs. 7.0  2.5
(SHAM), although more RDN patients (41 %) had medical changes than
SHAM pt (24 %).
CONCLUSIONS Renal denervation performed at a single center and
by a high volume operator reduced ASBP to the same level as SHAM
treatment. This result is in line with ﬁndings from the HTN3 trial.
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BACKGROUND In this study we investigated whether multi-electrode
catheter-based renal sympathetic denervation (RDN) has favorable
effects on left ventricular (LV) structural and functional indices
in patients with resistant hypertension after a follow-up of 24
months.
METHODS Twenty patients with resistant hypertension [age: 5710
years, 13 males, ofﬁce blood pressure (BP): 182/9719/18 mmHg under
4.50.6 drugs] who underwent RDN were followed-up for 24 months.
A full transthoracic echocardiographic study was performed in all
patients and LV mass was calculated using the Devereux formula and
was indexed for body surface area and height.
RESULTS Average ofﬁce BP was reduced to 14821/8514 mmHg at 12
months and to 14323/8014 mmHg at 24 months (p<0.001 for all). In
the RDN group, LV mass index was signiﬁcantly reduced from
13620.1 g/m2 (56.58.7 g/m2.7) to 12116.6 g/m2 (50.66 g/m2.7) at
12 months and to 115.623.3 g/m2 (48.89.3 g/m2.7) at 24 months
(p<0.01 for allþ). RDN decreased mean interventricular septum
thickness from 12.11.2 mm to 11.40.9 mm at 12 months and to
11.30.9 mm at 24 months (p<0.05 for all). After RDN, the number of
patients with concentric LV hypertrophy (i.e. relative wall
thickness>0.42 and LV mass>48 g/m2.7 for male and >44 g/m2.7 for
female) decreased from 16 patients (80%) at baseline to 10 patients
(50%) at 12 months, and to 7 patients (36.8%) at 24 months. Regarding
diastolic function RDN caused an increase in mitral valve E΄/A΄ ratio
from 0.620.28 to 0.700.25 at 12 months and to 0.840.32 at 24
months (p<0.05 for all) and a decrease in the E/E΄ ratio from 14.86.1
to 11.83.7 at 12 months and to 9.74 (p<0.05 for all).
CONCLUSIONS This the ﬁrst study to show that multi-electrode RDN
system results in a signiﬁcant and sustained improvement of diastolic
function and attenuation of LV mass index in increased cardiovas-
cular risk resistant hypertensive patients after a follow-up of 24
months. These results suggest pleiotropic cardiovascular beneﬁts of
RDN therapy in the setting of resistant hypertension.
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BACKGROUND Portico (St. Jude Medical) and CoreValve (Med-
tronic) are both nitinol based self-expanding transcatheter heart valves
with unique features enabling device retrievability for Portico and su-
pra annular valve position for CoreValve systems. In this study, we
sought to investigate the effect of the different self-expanding valve
design on hemodynamic and clinical performance when implanted for
degenerated aortic valve bioprosthesis (valve in valve, ViV).
METHODS Patients undergoing Portico implantation for degenerated
aortic bioprosthesis were compared to those undergoing CoreValve
implantation after matching for differences in age, gender, STS score,
arterial access, bioprosthesis valve design and label size in a 1:2
manner. Procedural and clinical outcomes were deﬁned by Valve
Academic Research Consortium II (VARC-II).
RESULTS A total of 135 patients that underwent ViV using a self-
expanding device were included in the analysis (age 798yrs, 61.5%
female). The group included 45 Portico implantations that were
matched with 90 CoreValve ViV patients having similar patient and
surgical valve characteristics. Baseline demographic and procedural
characteristics, echocardiographic and clinical outcomes are detailed
in the table. There were no differences in any procedural character-
istics between the two groups, except for the external transcatheter
valve diameter selected being signiﬁcantly greater for the CoreValve
ViV and proportion of patients undergoing procedure under
general anesthesia and with TEE guidance, which was signiﬁcantly
higher for the Portico group. Clinical outcomes were similar except
for major vascular complications that were signiﬁcantly lower in
Portico implantations. Site reported echocardiographic parameters
showed a greater proportion of patients with more than mild aortic
insufﬁciency after the procedure and a smaller effective oriﬁce area
for the Portico compared to CoreValve group. Blinded core lab analysis
of post implantation imaging of all cases analyzed is being completed.CONCLUSIONS Despite important design differences between the
two self-expanding transcatheter valves, both devices were safe
and effective for management of degenerated aortic bioprosthesis.
The present study has identiﬁed dissimilarities in hemodynamic
performance and clinical outcomes that require conﬁrmation in
future studies.Portico
(n[45)CoreValve
(n[90) P valueBaseline characteristicsSTS score, mean  SD 7.5  3.7 8.1  5.2 0.11
THV external
diameter, mean 
SD24  1 26  2 <0.05Clinical outcomes at 30 daysDeath, n (%) 1 (2.2) 4 (4.7) 0.5Stroke, n (%) 1 (2) 2 (2) 1Major vascular
complication, n (%)1 (2) 8 (9) 0.03Coronary obstruction
(%)0 (0) 4 (4.6) 0.30Malposition, n (%) 0 (0) 5 (6.0) 0.16Second prosthesis, n
(%)0 (0) 5 (5.6) 0.17Permanent pacemaker,
n (%)1 (3) 5 (6) 0.67> Mild aortic
insufﬁciency n (%)8 (18) 4 (5) 0.02EOA cm2, mean  SD 1.3  0.4 1.5  0.4 0.03
Mean gradient mmHg ,
mean  SD
17.1 8 15.5 8 0.30AKI- Acute Kidney Injury, EOA-effective oriﬁce area, PPM-permanent pacemaker, LVEF-left ventricle ejection
fraction, STS-Society of Thoracic Surgery score, TEE-transesophageal echocardiography, THV- Transcatheter
Heart Valve.
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BACKGROUND Transcatheter aortic valve replacement (TAVR) has
been established as alternative treatment for inoperable or high-risk
patients with symptomatic severe aortic stenosis. We sought to
evaluate the clinical outcomes of TAVR in Asian Paciﬁc countries.
METHODS The Asian TAVR registry was conducted in 12 centres from
6 countries between February 2009 and February 2015. Baseline de-
mographics, procedural and echocardiographic data were prospec-
tively collected from each center and entered into dedicated
electronic case report form.
RESULTS Nine hundred and forty patients were included. Mean
age was 82.1  6.5 years and 52.9% were female. Edwards SAPIEN/XT
and CoreValve were used in 65.4% and 34.6% of patients, respec-
tively. Approaches were either transarterial (transfemoral, 85.8%;
subclavian, 0.4%; direct aortic, 1.6%) or transapical (12.0%).
